{
    "clinical_study": {
        "@rank": "95915", 
        "acronym": "SAVE", 
        "arm_group": {
            "arm_group_label": "donepezil HCl 23 mg", 
            "arm_group_type": "Experimental", 
            "description": "Donepezil HCl 23 mg once daily, just before bed, for 24 weeks"
        }, 
        "brief_summary": {
            "textblock": "This is a multi-center, open-label, single-arm, prospective, phase IV trial, evaluating\n      safety and efficacy of donepezil hydrochloride in patients with moderate to severe\n      Alzheimer's disease."
        }, 
        "brief_title": "Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "detailed_description": {
            "textblock": "This study consisted of pre-treatment and treatment phase. Pre-treatment phase was\n      approximately 4 weeks including the screening and baseline process. In treatment phase,\n      about 190 subjects received Donepezil HCl 23 mg once daily for 24 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          1. Male or female aged 45 to 90 years\n\n          2. Patients have eligible conditions of dementia diagnosis listed in DSM-IV\n\n          3. Diagnosed as a probable Alzheimer's Disease patient according to NINCDS-ADRDA\n             criteria\n\n          4. At the timing of screening, MMSE less than or equal to 20 AND CDR greater than or\n             equal to 2 OR GDS greater than or equal to 4\n\n          5. Patients, who have been taking stable donepezil 10 mg for 3 months or longer before\n             the start of the study (screening visit), are evaluated as eligible to take donepezil\n             23 mg by investigator\n\n          6. Patients who have not received any other medications for AD such as AChE inhibitors\n             at least for 3 months prior to the screening visit excluding donepezil hydrochloride\n             (However, concomitant use of memantine is allowed if taken at stable dose that are\n             less than or equal to the approved dose range for at least 3 months prior to\n             screening)\n\n          7. Medicines for cerebral activation such as Gingko Biloba is allowed to be taken if the\n             patient has received it as stable dose for 3 months prior to the screening visit\n\n        Exclusion Criteria\n\n          1. Patients who have been participated in any other clinical trial 3 months prior to the\n             screening visit\n\n          2. Patients who are having any severe psychiatric disorder or schizophrenia\n\n          3. Patients who are having a neurological disorder other than AD which affect the\n             subject's cognition or ability to assess the cognition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "190", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097056", 
            "org_study_id": "ARI-M082-401"
        }, 
        "intervention": {
            "arm_group_label": "donepezil HCl 23 mg", 
            "description": "Donepezil HCl 23 mg once daily, just before bed, for 24 weeks", 
            "intervention_name": "donepezil HCL", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Donepezil"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Alzheimer's disease", 
        "lastchanged_date": "March 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chungju", 
                        "country": "Korea, Republic of", 
                        "state": "Chungcheongbuk-do"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gumi", 
                        "country": "Korea, Republic of", 
                        "state": "Geyongsangbuk-do"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ansan", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buchoen", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seongnam", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jinju", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeongsangnam-do"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iksan", 
                        "country": "Korea, Republic of", 
                        "state": "Jeollabuk-do"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hwasun", 
                        "country": "Korea, Republic of", 
                        "state": "Jeollanam-do"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeju", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease", 
        "overall_contact": {
            "email": "y-pyo@eisaikorea.com", 
            "last_name": "Youngji Pyo", 
            "phone": "+82-2-3451-5533"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety will be evaluated by all adverse events, serious adverse events, discontinuation from the treatment, prior and concomitant medication, clinical laboratory determinations (biochemistry, blood, urine test), vital signs, weight, ECG, and physical examination.", 
            "measure": "Safety of Donepezil HCl 23 mg once daily", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline up to Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097056"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "MMSE (Mini-Mental State Examination) and NPI-Q (Brief questionnaire form of the Neuropsychiatric Inventory) score will be used to evaluate efficacy. Mean change will be analyzed by paired t-test or Wilcoxon's signed rank test.", 
            "measure": "Efficacy of Donepezil HCl 23 mg once daily", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 12, and Week 24 (Final visit)"
        }, 
        "source": "Eisai Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Ministry of Food and Drug Safety, Korea", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Eisai Korea Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}